Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( <scp>INTEGUMENT</scp> ‐ <scp>OLE</scp> )
Authors
AA Hebert
Diane T. Hanna (ORCID: https://orcid.org/0000-0003-1162-9341)
Chesahna Kindred
David R. Berk
David Krupa
Mercedes E. Gonzalez
Vimal H. Prajapati
Rocco Serrao
Melissa S. Seal
Mark Boguniewicz
Scott Snyder
Lisa Swanson
Patrick Burnett
Lawrence F. Eichenfield
Tracy Funk
Institutions
Oregon Health & Science University (US)
National Jewish Health (US)
Rady Children's Hospital-San Diego (US)
Probity Medical Research (CA)
Skin Research Center (FR)
Atara Biotherapeutics (United States) (US)
The University of Texas Health Science Center at Houston (US)
Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )
AA Hebert, Diane T. Hanna, Chesahna Kindred, David R. Berk et al.
Journal
Pediatric Dermatology
Topics
Dermatology and Skin Diseases
article
Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )
AA Hebert, Diane T. Hanna, Chesahna Kindred, David R. Berk, David Krupa, Mercedes E. Gonzalez, Vimal H. Prajapati, Rocco Serrao, Melissa S. Seal, Mark Boguniewicz, Scott Snyder, Lisa Swanson, Patrick Burnett, Lawrence F. Eichenfield, Tracy Funk
article en
Abstract
No abstract available for this paper.
Publication Tag
Pediatric Dermatology
Institutions
Oregon Health & Science University (US), National Jewish Health (US), Rady Children's Hospital-San Diego (US), Probity Medical Research (CA), Skin Research Center (FR), Atara Biotherapeutics (United States) (US), The University of Texas Health Science Center at Houston (US), University of Colorado Denver (US)